



NEWS RELEASE

# Shattuck Labs Announces Participation in Upcoming March Conferences

2024-02-26

AUSTIN, TX and DURHAM, NC, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced that company management will participate in multiple investor conferences in March 2024.

## **Presentation Details**

Conference: TD Cowen 44th Annual Health Care Conference

Format: Panel Discussion and 1x1 Meetings

Panel Topic: Novel IO Corporate Panel Discussion

- Presenter: Dr. Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer
- Date: March 4, 2024
- Time: 10:30-11:30 a.m. ET

Conference: Leerink Partners Global Biopharma Conference 2024

Format: 1x1 Meetings

Dates: March 11-12, 2024

Conference: Citi's Biotech C-Suite Fireside Chat Series

Format: Fireside chat with covering analyst Yigal Nochomovitz, Ph.D.

- Presenters: Dr. Taylor Schreiber, M.D., Ph.D., Shattuck's Chief Executive Officer and Andrew Neill, M.B.A., Shattuck's Chief Financial Officer
- Date: March 20, 2024
- Time: 11:00 a.m. ET

A live webcast of the presentations will be available on the Investors section of the Company's website. A replay of the webcast will be archived for up to 30 days following the presentation date.

## **About Shattuck Labs, Inc.**

Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck's proprietary Agonist Redirected Checkpoint, ("ARC®"), platform are designed to simultaneously inhibit checkpoint molecules and activate costimulatory molecules with a single therapeutic. The company's lead SL-172154 (SIRP $\alpha$ -Fc-CD40L) program, which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in multiple Phase 1 trials. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: [www.ShattuckLabs.com](http://www.ShattuckLabs.com).

**Investor & Media Contact:**

Conor Richardson  
Vice President of Investor Relations  
Shattuck Labs, Inc.  
[InvestorRelations@shattucklabs.com](mailto:InvestorRelations@shattucklabs.com)

Source: Shattuck Labs, Inc.